Quarterly report · Q2
4323.TEDINET S100PJPL
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥21.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥992m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.0bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥738m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥687m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥748m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥692m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥15.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥15.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥14.2bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥6.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥9.9bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥9.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.0bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥819m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥839m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥86m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥81m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥57m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥273m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥487m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥593m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥60.16 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.91 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.32 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.22 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.16 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.5% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥89m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥852m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥19m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥184m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥719m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥719m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥71m |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28m |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥556m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥11.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥89m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥33m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥33m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥764m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥906m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥897m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥203,000 |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥740m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥740m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥131m |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥786m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥10.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥33m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 547
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash dividends paid fin cf | Prior1YTDDuration | -152028000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -248274000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YTDDuration | － | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | -1680000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 592943000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -273422000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 31654000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 102663000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 1406061000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 562355000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 4853695000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 6463823000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 6259757000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 7026178000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 654004000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 708849000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 157886000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 176740000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 15319000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 34231000 | JPY |
| Directors share based compensation expenses sga | Prior1YTDDuration | 7468000 | JPY |
| Directors share based compensation expenses sga | CurrentYTDDuration | 11908000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 1197000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 352000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 25070000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 28196000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 160460000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 199771000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 6273041000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 2131669000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000MedicalBigDataBusinessReportableSegmentMember | 740496000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000GlobalBusinessReportableSegmentMember | 897267000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 10042475000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 10042475000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 22566000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 2475000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000MedicalBigDataBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000GlobalBusinessReportableSegmentMember | 8412000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 33454000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -33454000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 6295608000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 2134144000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000MedicalBigDataBusinessReportableSegmentMember | 740496000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000GlobalBusinessReportableSegmentMember | 905679000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 10075929000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -33454000 | JPY |
| Net sales | Prior1YTDDuration | 10042475000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 839188000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |